Literature DB >> 26431630

Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation.

Claudio G Brunstein1, Effie W Petersdorf2, Todd E DeFor3, Harriet Noreen4, David Maurer4, Margaret L MacMillan3, Celalettin Ustun3, Michael R Verneris3, Jeffrey S Miller3, Bruce R Blazar3, Philip B McGlave3, Daniel J Weisdorf3, John E Wagner3.   

Abstract

The impact of allele-level HLA mismatch is uncertain in recipients of double umbilical cord blood (UCB) transplantation. We report a single-center retrospective study of the clinical effect of using allele-level HLA mismatch HLA-A, -B, -C, -DRB1, and -DQB1 of the 2 UCB units. We studied 342 patients with hematologic malignancy. Donor-recipient pairs were grouped according to the number of matched HLA alleles, with 32 matched at 9-10/10, 202 at 6-8/10, and 108 at 2-5/10 alleles. The incidence of hematopoietic recovery, acute and chronic graft-versus-host disease, and nonrelapse mortality and treatment failure was similar between groups. In an exploratory analysis of 174 patients with acute leukemia, after adjusting for length of first remission and cytogenetic risk group, a 2-5/10 HLA match was associated with lower risk of relapse and treatment failure. These data indicate that a high degree of allele-level HLA mismatch does not adversely affect transplant outcomes and may be associated with reduced relapse risk in patients with acute leukemia.
Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alternative donor transplant; Histocompatibility; Umbilical cord blood

Mesh:

Substances:

Year:  2015        PMID: 26431630      PMCID: PMC4753126          DOI: 10.1016/j.bbmt.2015.09.025

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  25 in total

1.  Validation of DNA-based HLA-A and HLA-B testing of volunteers for a bone marrow registry through parallel testing with serology.

Authors:  H J Noreen; N Yu; M Setterholm; M Ohashi; J Baisch; R Endres; M Fernandez-Vina; U Heine; S Hsu; M Kamoun; Y Mitsuishi; D Monos; L Perlee; S Rodriguez-Marino; A Smith; S Y Yang; K Shipp; J Hegland; C K Hurley
Journal:  Tissue Antigens       Date:  2001-03

2.  HLA-DRB1 DNA sequencing based typing: an approach suitable for high throughput typing including unrelated bone marrow registry donors.

Authors:  D Sayer; R Whidborne; B Brestovac; F Trimboli; C Witt; F Christiansen
Journal:  Tissue Antigens       Date:  2001-01

3.  One-unit versus two-unit cord-blood transplantation for hematologic cancers.

Authors:  John E Wagner; Mary Eapen; Shelly Carter; Yanli Wang; Kirk R Schultz; Donna A Wall; Nancy Bunin; Colleen Delaney; Paul Haut; David Margolis; Edward Peres; Michael R Verneris; Mark Walters; Mary M Horowitz; Joanne Kurtzberg
Journal:  N Engl J Med       Date:  2014-10-30       Impact factor: 91.245

4.  Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia.

Authors:  Andromachi Scaradavou; Claudio G Brunstein; Mary Eapen; Jennifer Le-Rademacher; Juliet N Barker; Nelson Chao; Corey Cutler; Colleen Delaney; Fangyu Kan; Luis Isola; Chatchada Karanes; Mary J Laughlin; John E Wagner; Elizabeth J Shpall
Journal:  Blood       Date:  2012-12-09       Impact factor: 22.113

5.  Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia.

Authors:  Yoshiko Atsuta; Junya Kanda; Minoko Takanashi; Yasuo Morishima; Shuichi Taniguchi; Satoshi Takahashi; Hiroyasu Ogawa; Kazuteru Ohashi; Yuju Ohno; Yasushi Onishi; Nobuyuki Aotsuka; Tokiko Nagamura-Inoue; Koji Kato; Yoshinobu Kanda
Journal:  Haematologica       Date:  2013-01-24       Impact factor: 9.941

6.  Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice.

Authors:  Eliane Gluckman; Vanderson Rocha; William Arcese; Gérard Michel; Guillermo Sanz; Ka-Wah Chan; Tsuneo A Takahashi; Juan Ortega; Alexandra Filipovich; Franco Locatelli; Shigetaka Asano; Franca Fagioli; Marcus Vowels; Anne Sirvent; Jean-Philippe Laporte; Karin Tiedemann; Sergio Amadori; Manuel Abecassis; Pierre Bordigoni; Blanca Diez; Peter J Shaw; Ajay Vora; Maurizio Caniglia; Federico Garnier; Irina Ionescu; Joan Garcia; Gesine Koegler; Paolo Rebulla; Sylvie Chevret
Journal:  Exp Hematol       Date:  2004-04       Impact factor: 3.084

7.  Impact on outcomes of human leukocyte antigen matching by allele-level typing in adults with acute myeloid leukemia undergoing umbilical cord blood transplantation.

Authors:  Jaime Sanz; Francisco J Jaramillo; Dolores Planelles; Pau Montesinos; Ignacio Lorenzo; Federico Moscardó; Guillermo Martin; Francisca López; Jesús Martínez; Isidro Jarque; Javier de la Rubia; Luis Larrea; Miguel A Sanz; Guillermo F Sanz
Journal:  Biol Blood Marrow Transplant       Date:  2014-01       Impact factor: 5.742

Review 8.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

9.  The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation.

Authors:  E W Petersdorf; G M Longton; C Anasetti; P J Martin; E M Mickelson; A G Smith; J A Hansen
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

10.  Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry.

Authors:  K Atkinson; M M Horowitz; R P Gale; M B Lee; A A Rimm; M M Bortin
Journal:  Bone Marrow Transplant       Date:  1989-05       Impact factor: 5.483

View more
  13 in total

1.  Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases.

Authors:  Giancarlo Fatobene; Fernanda Volt; Frederico Moreira; Lívia Mariano; Patrice Chevallier; Sabine Furst; Hélène Labussière-Wallet; Régis Peffault de la Tour; Eric Deconinck; Thomas Cluzeau; Nigel Russell; Dimitrios Karakasis; Edouard Forcade; Annalisa Ruggeri; Eliane Gluckman; Vanderson Rocha
Journal:  Blood Adv       Date:  2020-12-22

Review 2.  Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.

Authors:  Juliet N Barker; Joanne Kurtzberg; Karen Ballen; Michael Boo; Claudio Brunstein; Corey Cutler; Mitchell Horwitz; Filippo Milano; Amanda Olson; Stephen Spellman; John E Wagner; Colleen Delaney; Elizabeth Shpall
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-06       Impact factor: 5.742

3.  Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts.

Authors:  Claudio G Brunstein; Corey S Cutler; Todd E DeFor; Haesook Kim; Nelli Bejanyan; Alfred Garfall; Michael R Verneris; Yi-Bin Chen; Erica D Warlick; Thomas Spitzer; Jeffrey S Miller; Joseph H Antin; Daniel J Weisdorf; Robert Soiffer; John E Wagner; Karen K Ballen
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-29       Impact factor: 5.742

4.  Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia.

Authors:  Jaime Sanz; Mi Kwon; Guiomar Bautista; Miguel A Sanz; Pascual Balsalobre; José Luis Piñana; Carlos Solano; Rafael Duarte; Christelle Ferrá; Ignacio Lorenzo; Carmen Martín; Pere Barba; María Jesús Pascual; Rodrigo Martino; Jorge Gayoso; Ismael Buño; Carmen Regidor; Almudena de la Iglesia; Juan Montoro; José Luis Díez-Martín; Guillermo F Sanz; Rafael Cabrera
Journal:  Blood Adv       Date:  2017-06-20

5.  High progression-free survival after intermediate intensity double unit cord blood transplantation in adults.

Authors:  Juliet N Barker; Sean M Devlin; Kristine A Naputo; Kelcey Skinner; Molly A Maloy; Lisa Flynn; Theodora Anagnostou; Scott T Avecilla; Andromachi Scaradavou; Christina Cho; Parastoo B Dahi; Sergio A Giralt; Boglarka Gyurkocza; Alan M Hanash; Katharine Hsu; Ann A Jakubowski; Esperanza B Papadopoulos; Jonathan U Peled; Miguel-Angel Perales; Craig S Sauter; Gunjan L Shah; Brian C Shaffer; Roni Tamari; James W Young; Mikhail Roshal; Richard J O'Reilly; Doris M Ponce; Ioannis Politikos
Journal:  Blood Adv       Date:  2020-12-08

6.  HLA-DPB1 mismatch induces a graft-versus-leukemia effect without severe acute GVHD after single-unit umbilical cord blood transplantation.

Authors:  T Yabe; F Azuma; K Kashiwase; K Matsumoto; T Orihara; H Yabe; S Kato; K Kato; S Kai; T Mori; S Morishima; M Satake; M Takanashi; K Nakajima; Y Morishima
Journal:  Leukemia       Date:  2017-06-27       Impact factor: 11.528

Review 7.  Graft predominance after double umbilical cord blood transplantation: a review.

Authors:  Jan J Cornelissen; Burak Kalin; Cor H J Lamers
Journal:  Stem Cell Investig       Date:  2017-05-26

8.  The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia.

Authors:  Amy K Keating; Jurgen Langenhorst; John E Wagner; Kristin M Page; Paul Veys; Robert F Wynn; Heather Stefanski; Reem Elfeky; Roger Giller; Richard Mitchell; Filippo Milano; Tracey A O'Brien; Ann Dahlberg; Colleen Delaney; Joanne Kurtzberg; Michael R Verneris; Jaap Jan Boelens
Journal:  Blood Adv       Date:  2019-04-09

9.  Evaluation of post-thaw CFU-GM: clinical utility and role in quality assessment of umbilical cord blood in patients receiving single unit transplant.

Authors:  Eiman Hussein; Todd DeFor; John E Wagner; Darin Sumstad; Claudio G Brunstein; David H McKenna
Journal:  Transfusion       Date:  2019-11-22       Impact factor: 3.157

10.  Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide.

Authors:  Scott R Solomon; Michael T Aubrey; Xu Zhang; Katelin C Jackson; Lawrence E Morris; H Kent Holland; Melhem M Solh; Asad Bashey
Journal:  Blood Adv       Date:  2020-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.